dihexa fda approval status 2026 human trials or clinical studies trial dihexa SCOPE 2026, Simplified Patient Recruitment Management, AI Powered Clinical Trial Finders dihexa fda approval status 2026 – dihexa clinical trial AHK-Cu - 10 g Quantity:1 Bottle megaloblastic anemia treatment

dihexa fda approval status 2026 human trials or clinical studies trial dihexa SCOPE 2026, Simplified Patient Recruitment Management, AI Powered Clinical Trial Finders dihexa fda approval status 2026 – dihexa clinical trial AHK-Cu - 10 g Quantity:1 Bottle megaloblastic anemia treatment

AHK-Cu - 10 g (10% Concentrate, 100,000 ppm) – Lrak Technologies

Those with minimal early response may have biological factors limiting their response, but this represents baseline responsiveness rather than declining effectiveness over time

megaloblastic anemia treatment

Quantity:1 Bottle

Phase 3: Maintenance (Weeks 9–12) Dose: 1.6–4.8 mg, 2-3x per week Pulsed administration keeps the repair signal present without turning the protocol into constant stimulation